Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03146013 · ClinicalTrials.gov registry record
Dual Algorithm Post Market Clinical Study
A clinical trial, sponsored by MP Biomedicals.
- Completed
- Registry status
- 100
- Enrollment target
NCT03146013 is a clinical trial that has completed, run by MP Biomedicals. The registered enrollment target is 100 participants.
The verdict
NCT03146013 has completed, sponsored by MP Biomedicals.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).
Interventions
- DIAGNOSTIC_TEST MP Diagnostics HTLV Blot 2.4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2017-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03146013
The ClinicalTrials.gov registry entry for NCT03146013 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MP Biomedicals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MP Diagnostics HTLV Blot 2.4 is the first listed.
NCT03146013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03146013 about?
NCT03146013 is a clinical study titled "Dual Algorithm Post Market Clinical Study". The purpose of this study is to assess the validity and reproducibility of the MP Diagnostics HTLV Blot 2.4 in blood specimens testing repeat reactive (RR) on the first FDA licensed screening assay (Abbott Prism) and non-reactive (NR) on the second FDA licensed screening assay (Avioq ELISA).
What is the current status of trial NCT03146013?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2017-03-01. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT03146013?
The interventions under investigation include: MP Diagnostics HTLV Blot 2.4 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03146013?
This trial is sponsored by MP Biomedicals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.